InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China

By /

InnoCare Pharma announced the first psoriasis patient has been dosed in clinical trial of the Company’s TYK2 JH2 allosteric inhibitor ICP-488 in China.

Scroll to Top